Illumina closed on GRAIL before regulators had ruled

The record

Illumina completed its acquisition of cancer-screening company GRAIL on 18 August 2021, under a merger agreement dated 20 September 2020, as its own Form 8-K from that date confirms. It closed while antitrust review was still open in two jurisdictions. Illumina's fiscal 2023 Form 10-K sets out the sequence: the FTC filed an administrative complaint in March 2021; an administrative law judge ruled for Illumina in September 2022; the full Commission reversed that ruling on 31 March 2023 and ordered divestiture; and on 15 December 2023 the Fifth Circuit upheld the Commission's decision in most respects while vacating and remanding one narrower issue. In parallel, the European Commission obtained jurisdiction through an Article 22 referral from a member state, adopted a prohibition decision on 6 September 2022, and issued a divestment decision on 12 October 2023. Illumina completed the divestiture through a spin-off, distributing roughly 85.5% of GRAIL's shares to Illumina stockholders on 24 June 2024, one GRAIL share for every six Illumina shares, per its own Form 8-K of that date.

What the documents establish

These are Illumina's own disclosures of a multi-year, two-jurisdiction regulatory record, not a single agency's press statement. They establish that Illumina chose to close before either the FTC's administrative process or the EU's jurisdictional and merits review had concluded, a sequence the 10-K itself frames as ongoing legal risk rather than a resolved matter even as of its February 2024 filing date. The Fifth Circuit's partial vacatur, on the narrower question of how the Commission assessed a specific contractual term, is a real limit on the FTC's order, distinct from the order's broader survival.

The operating read

Editorially, this sequence is the clearest contrast in this batch to a deal like Broadcom-VMware or Cisco-Splunk, which closed only after clearance. Closing first let Illumina and GRAIL operate as one company for nearly three years while two regulators worked toward the opposite conclusion, and the eventual unwind proceeded on Illumina's own schedule, by spin-off, rather than a court-ordered sale to a specific buyer.

What to check before you decide

Before assuming a completed deal is a settled deal, check what its own disclosures still describe as open.

• Does the acquirer's own SEC filing disclose ongoing antitrust litigation as unresolved, even after the deal has closed?
• Is a regulator's order final, or has it been appealed, stayed, or partially vacated and remanded?
• Does a divestiture return the business to its original ownership structure, or restructure it differently, such as through a public spin-off rather than a private sale?

Illumina's own filings record a deal that closed in 2021 and was still being litigated and unwound three years later, a timeline no single press release from either regulator would fully capture on its own.